Strides Pharma Science Croissance future
Future contrôle des critères 5/6
Strides Pharma Science devrait augmenter ses bénéfices et son chiffre d'affaires de 24.4% et de 16.9% par an respectivement. Le BPA devrait croître de de 24.4% par an. Le rendement des capitaux propres devrait être 21.8% dans 3 ans.
Informations clés
24.4%
Taux de croissance des bénéfices
24.39%
Taux de croissance du BPA
| Pharmaceuticals croissance des bénéfices | 16.1% |
| Taux de croissance des recettes | 16.9% |
| Rendement futur des capitaux propres | 21.75% |
| Couverture par les analystes | Low |
| Dernière mise à jour | 18 May 2026 |
Mises à jour récentes de la croissance future
Recent updates
STAR: Upcoming Results, Dividend Proposal And Auditor Change Will Shape Balanced Outlook
Analysts have kept the price target for Strides Pharma Science broadly steady at about ₹1,119, citing only small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E that do not materially change their valuation view. What's in the News A board meeting is scheduled on May 18, 2026 at 12:30 Indian Standard Time to review and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
STAR: Upcoming Results And Dividend Decision Will Shape Fairly Valued Outlook
Analysts have raised their price target on Strides Pharma Science from ₹1,078.50 to ₹1,264.00, citing updated assumptions that include higher projected revenue growth, a slightly stronger profit margin profile, a modestly lower discount rate, and a somewhat higher future P/E multiple. What's in the News A board meeting is scheduled on May 18, 2026, to review and approve the audited standalone and consolidated financial results for the quarter and full year ended March 31, 2026 (Key Developments).
STAR: Higher Revenue And Margin Assumptions Will Support Stronger Returns Ahead
Analysts have maintained their price target for Strides Pharma Science at ₹1,409, citing updated assumptions that reflect slightly higher revenue growth and profit margin expectations, along with a modestly lower future P/E multiple in their models. Valuation Changes Fair Value: Model fair value remains unchanged at ₹1,409.0 per share.STAR: Upcoming Results Meeting And Revised Assumptions Will Support Bullish Thesis
Analysts have lifted their price target on Strides Pharma Science from ₹1,085 to ₹1,119, pointing to revised assumptions that include slightly higher revenue growth, a modestly lower profit margin and a small uplift in the future P/E multiple. What's in the News A board meeting is scheduled for January 30, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, along with other agenda items (company filing).STAR: Higher Revenue Assumptions Will Support Stronger Profit Margins Ahead
Analysts have raised their price target on Strides Pharma Science from ₹1,220 to ₹1,409, citing updated assumptions for revenue growth, profit margins and future P/E that collectively support a higher fair value estimate under a slightly lower discount rate. What's in the News A board meeting is scheduled for January 30, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, along with other matters (company filing).STAR: Future Earnings Meeting And Margin Outlook Will Support Bullish Thesis
Analysts have lifted their price target on Strides Pharma Science from ₹937 to ₹1,085, citing updated assumptions for revenue growth, profit margins and the future P/E multiple, as well as a slightly lower discount rate. What's in the News The board has scheduled a meeting on January 30, 2026 to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, along with other matters (company filing).Affordable Generics And Digital Trends Will Broaden Global Healthcare Reach
With both Net Profit Margin and Revenue Growth forecasts remaining stable, analysts made no substantive changes to their outlook, resulting in the consensus price target for Strides Pharma Science holding steady at ₹1078. What's in the News Board meeting scheduled to consider and approve Q1 FY26 unaudited financial results, share allotment, and amendments to the company's fair disclosure policy.
US Product Launches And ESG Leadership Will Strengthen Future Market Position
Streamlined focus on high-margin operations and U.S. market expansion indicate a strong growth trajectory and improved future earnings.Strides Pharma Science's (NSE:STAR) Solid Earnings Are Supported By Other Strong Factors
Even though Strides Pharma Science Limited's ( NSE:STAR ) recent earnings release was robust, the market didn't seem to...Why Investors Shouldn't Be Surprised By Strides Pharma Science Limited's (NSE:STAR) 27% Share Price Surge
Despite an already strong run, Strides Pharma Science Limited ( NSE:STAR ) shares have been powering on, with a gain of...After Leaping 29% Strides Pharma Science Limited (NSE:STAR) Shares Are Not Flying Under The Radar
Despite an already strong run, Strides Pharma Science Limited ( NSE:STAR ) shares have been powering on, with a gain of...Investors Still Waiting For A Pull Back In Strides Pharma Science Limited (NSE:STAR)
With a median price-to-sales (or "P/S") ratio of close to 2.4x in the Pharmaceuticals industry in India, you could be...Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Strides Pharma Science Limited's (NSE:STAR) Shares Leap 31% Yet They're Still Not Telling The Full Story
Strides Pharma Science Limited ( NSE:STAR ) shareholders have had their patience rewarded with a 31% share price jump...We Think Strides Pharma Science (NSE:STAR) Is Taking Some Risk With Its Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Strides Pharma Science Limited (NSE:STAR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
Last week saw the newest quarterly earnings release from Strides Pharma Science Limited ( NSE:STAR ), an important...Is Strides Pharma Science (NSE:STAR) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 3/31/2028 | 68,263 | 8,943 | 6,565 | 9,473 | 2 |
| 3/31/2027 | 58,080 | 6,266 | 4,805 | 7,305 | 1 |
| 3/31/2026 | 48,587 | 5,562 | 2,846 | 7,025 | N/A |
| 12/31/2025 | 47,256 | 5,114 | N/A | N/A | N/A |
| 9/30/2025 | 46,846 | 3,973 | 3,989 | 6,960 | N/A |
| 6/30/2025 | 46,307 | 3,416 | N/A | N/A | N/A |
| 3/31/2025 | 45,653 | 4,053 | 4,419 | 6,844 | N/A |
| 12/31/2024 | 45,794 | 3,424 | N/A | N/A | N/A |
| 9/30/2024 | 44,103 | 1,771 | 6,344 | 8,172 | N/A |
| 6/30/2024 | 42,086 | -475 | N/A | N/A | N/A |
| 3/31/2024 | 38,901 | -1,202 | 5,829 | 7,011 | N/A |
| 12/31/2023 | 39,535 | -1,525 | N/A | N/A | N/A |
| 9/30/2023 | 37,806 | -2,280 | 3,043 | 3,903 | N/A |
| 6/30/2023 | 36,783 | -924 | N/A | N/A | N/A |
| 3/31/2023 | 36,884 | -2,212 | -505 | 444 | N/A |
| 12/31/2022 | 35,680 | -1,824 | N/A | N/A | N/A |
| 9/30/2022 | 34,976 | -2,241 | -2,101 | -1,144 | N/A |
| 6/30/2022 | 33,220 | -3,909 | N/A | N/A | N/A |
| 3/31/2022 | 30,703 | -4,602 | -4,012 | -2,578 | N/A |
| 12/31/2021 | 31,127 | -4,425 | N/A | N/A | N/A |
| 9/30/2021 | 31,504 | -2,830 | -1,188 | 1,572 | N/A |
| 6/30/2021 | 32,224 | -543 | N/A | N/A | N/A |
| 3/31/2021 | 33,159 | 2,545 | 1,840 | 4,814 | N/A |
| 12/31/2020 | 30,260 | 28 | N/A | N/A | N/A |
| 9/30/2020 | 29,264 | 589 | 970 | 2,699 | N/A |
| 6/30/2020 | 28,480 | 1,266 | N/A | N/A | N/A |
| 3/31/2020 | 27,520 | 492 | 548 | 2,048 | N/A |
| 12/31/2019 | 35,828 | 2,859 | N/A | N/A | N/A |
| 9/30/2019 | 34,203 | 2,169 | N/A | 1,896 | N/A |
| 6/30/2019 | 32,248 | 745 | N/A | N/A | N/A |
| 3/31/2019 | 21,784 | 840 | N/A | 601 | N/A |
| 12/31/2018 | 28,547 | -93 | N/A | N/A | N/A |
| 9/30/2018 | 28,090 | 139 | N/A | N/A | N/A |
| 6/30/2018 | 28,451 | 415 | N/A | N/A | N/A |
| 3/31/2018 | 28,451 | 544 | N/A | 1,871 | N/A |
| 12/31/2017 | 35,810 | 1,050 | N/A | N/A | N/A |
| 9/30/2017 | 36,593 | 1,124 | N/A | N/A | N/A |
| 6/30/2017 | 35,357 | 1,712 | N/A | N/A | N/A |
| 3/31/2017 | 27,554 | 2,335 | N/A | 2,881 | N/A |
| 12/31/2016 | 37,237 | 2,840 | N/A | N/A | N/A |
| 9/30/2016 | 36,573 | 2,410 | N/A | N/A | N/A |
| 6/30/2016 | 34,189 | 2,168 | N/A | N/A | N/A |
| 3/31/2016 | 28,622 | 1,317 | N/A | 732 | N/A |
| 12/31/2015 | 24,901 | 1,152 | N/A | N/A | N/A |
| 9/30/2015 | 12,962 | 860 | N/A | N/A | N/A |
| 6/30/2015 | 12,105 | 244 | N/A | N/A | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de STAR ( 24.4% par an) est supérieure au taux d'épargne ( 6.9% ).
Bénéfices vs marché: Les bénéfices de STAR ( 24.4% par an) devraient croître plus rapidement que le marché Indian ( 16.1% par an).
Croissance élevée des bénéfices: Les bénéfices de STAR devraient augmenter de manière significative au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de STAR ( 16.9% par an) devrait croître plus rapidement que le marché Indian ( 10.8% par an).
Croissance élevée des revenus: Le chiffre d'affaires de STAR ( 16.9% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de STAR devrait être élevé dans 3 ans ( 21.8 %)
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/06/10 01:38 |
| Cours de l'action en fin de journée | 2026/06/10 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2026/03/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Strides Pharma Science Limited est couverte par 14 analystes. 2 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Aditya Khemka | Ambit Capital |
| Harith Ahamed | Avendus Spark |
| Prakash Agarwal | Axis Capital Limited |